Developer docs
API playgroundTry for free, no card

Search company profiles

SARomics Biostructures

Full company profile

uuid000blc6

Namestring
SARomics Biostructures
Legal namestring
SARomics Biostructures AB
Websiteurl
saromics.com
Company typeenum
Private
Founded yearint
2006
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLund, Sweden
HQ citystring
Lund
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
structural biology services, x-ray crystallography services, protein structure determination, fragment screening services, drug discovery services
Industry2 codes
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGADAK
Material Characterization & Spectroscopy (NMR/FTIR/MS)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Structural Biology Contract Research Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Research Services
TypeProfessional Services
Description

Fee-for-service model with payments scheduled against specific project milestones. Includes initial startup fee and subsequent payments tied to project progress. FTE-based payments available upon agreement with customer.

saromics.com
2Structural Biology Services
TypeProfessional Services
Description

Services include protein crystallization and structure determination, fragment screening, hit identification, and structure-based lead generation and optimization. Revenue generated through project-based contracts with pharmaceutical, biotech, and academic clients.

saromics.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Fee-for-service with milestone payments
ModelOtherBilling cadenceMulti-year contract
Notes

Services provided on fee-for-service basis with payments scheduled against specific project milestones including initial startup fee and subsequent payments tied to project progress. FTE-based payments available upon agreement.

saromics.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

SARomics Biostructures is a contract research organization (CRO) that delivers fee-for-service structural biology and drug discovery projects for pharmaceutical, biotech, and academic clients. Its core services include protein X-ray crystallography, BioNMR spectroscopy, crystallographic and WAC™ fragment screening, antibody epitope mapping, higher-order structure (HOS) analysis, and structure-based lead optimization, supported by its FastLane™ protein catalog and priority access to the MAX IV synchrotron beamlines.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Over 100 structural biology and drug discovery projects completed annually
+4 more records
Product overview1 text field

SARomics Biostructures offers an integrated structural biology and drug discovery services platform combining X-ray crystallography, BioNMR spectroscopy, proprietary WAC™ fragment screening technology, and FastLane™ off-the-shelf protein catalogs. The platform enables gene-to-structure workflows, crystallographic fragment screening, NMR-based higher-order structure analysis, and DNA-encoded library screening (in partnership with Vipergen). Key offerings include custom protein structure determination, antibody epitope mapping, biosimilar comparability studies, and structure-based lead optimization services for biotech, pharmaceutical, and academic clients worldwide.

Product and service1 record
1X-ray Crystallography Services
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

Strategic collaboration announced April 2026 combining structural biology services including protein X-ray crystallography and structure-based drug discovery. Aims to streamline workflows, reduce redundancy, and expand service capabilities. SARomics brings 20 years of experience, Accelero brings 10+ years.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-11
Description

Strategic partnership to offer enhanced hit and lead identification services combining Vipergen's DNA-encoded library (DEL) screening technologies with SARomics' structural biology capabilities. Vipergen's DEL screening can identify novel hits from over 500 million drug-like molecules, while SARomics provides detailed structural information including binding site mapping and binding poses.

3LundaGUARD Consortium
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Consortium to fight infectious agents including LP3 (Protein Production Platform at Lund University), MAX IV, ESS, and University College London. Leverages WAC-screening platform for COVID-19 drug discovery.

saromics.com
4Carna Biosciences Inc.
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2016-08-01
Description

Exclusive distribution agreement covering Japanese market for SARomics services.

saromics.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2010-01-01
Description

Partnership for customized gene-to-structure projects, utilizing Vectron's expertise in protein production and SARomics' expertise in protein crystallization and structure determination.

6Red Glead Discovery
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Close collaboration on integrated drug discovery projects including WAC fragment screening technology (jointly owned), gene-to-lead projects, and various pharmaceutical partnerships. Partners on EU projects including Virus-X, BIOCASCADES, and others.

saromics.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership for FragMAX fragment screening platform and access to BioMax and MicroMax beamlines for X-ray crystallography. Located just kilometers from SARomics labs at Medicon Village.

Strategic tierCoreTypeTechnology or Integration
Description

Collaboration on FragMAX platform for crystallographic fragment screening, including design of kinase-focused fragment library developed with Jens Carlsson, Szymon Pach, and Philip Ullmann from Uppsala University.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Munich-based structural biology CRO offering protein crystallography, fragment screening (Pioneer™), and structure-based drug discovery services to pharma and biotech. Closest direct competitor to SARomics with very similar service portfolio and target customer base.

TypeDirect peer
Description

Dutch structural biology CRO specializing in protein crystallography, fragment screening by NMR and X-ray, and structure-based drug design. Highly comparable niche CRO competing for similar biotech and pharma accounts.

TypeBroad incumbent
Description

Large global CRO/CDMO with structural biology and fragment-based drug discovery capabilities embedded in a much broader service portfolio. Represents the scaled incumbent SARomics competes against for larger pharma contracts.

TypeBroad incumbent
Description

Major CRO with extensive structural biology, protein sciences, and drug discovery offerings across a global footprint. Serves as the dominant scaled alternative for enterprises considering structural biology outsourcing.

TypeDirect peer
Description

UK-based CRO offering integrated drug discovery including protein crystallography, fragment screening, and medicinal chemistry. Comparable niche CRO targeting similar biotech and pharma customers.

6Astex Pharmaceuticals
TypeDirect peer
Description

Fragment-based drug discovery specialist using X-ray crystallography and proprietary fragment libraries (e.g., Pyramid™). Direct overlap with SARomics' fragment screening and structure-based lead optimization services.

TypeBroad incumbent
Description

Computational chemistry and structure-based drug design platform with growing wet-lab/biopharma collaborations. Adjacent and partially overlapping in the structure-based design value chain.

TypeBroad incumbent
Description

Massive global CRO/CDMO offering structural biology alongside a full suite of discovery, development, and manufacturing services. Represents a competitive threat on price, scale, and global account coverage.

TypeEmerging player
Description

Danish DNA-encoded library screening technology provider. SARomics' partner in DEL screening services; comparable as an emerging platform player intersecting with SARomics' hit identification pipeline.

10Carna Biosciences
TypeRegional player
Description

Japan-based kinase-focused drug discovery CRO and SARomics' exclusive Japanese distributor. Operates in adjacent kinase biology and serves as both a partner and a partial competitor in APAC structural biology services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SARomics Biostructures

Structural Biology Contract Research Servicessaromics.com

SARomics Biostructures firmographics

Firmographics
Name
SARomics Biostructures
Legal name
SARomics Biostructures AB
Website
https://saromics.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

SARomics Biostructures industry classification

Industry
Product category
Structural Biology Contract Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGADAK
Material Characterization & Spectroscopy (NMR/FTIR/MS)

Keywords

  • Structural biology services
  • X-ray crystallography services
  • Protein structure determination
  • Fragment screening services
  • Drug discovery services

Where SARomics Biostructures is headquartered

Location

Headquarters

HQ city
Lund
HQ country
Sweden
HQ region
Europe

Offices3 records

Markets served

SARomics Biostructures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Services: Fee-for-service model with payments scheduled against specific project milestones. Includes initial startup fee and subsequent payments tied to project progress. FTE-based payments available upon agreement with customer.
  2. Structural Biology Services: Services include protein crystallization and structure determination, fragment screening, hit identification, and structure-based lead generation and optimization. Revenue generated through project-based contracts with pharmaceutical, biotech, and academic clients.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractFee-for-service with milestone payments

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

SARomics Biostructures product offering

Product offering

Core offering

SARomics Biostructures is a contract research organization (CRO) that delivers fee-for-service structural biology and drug discovery projects for pharmaceutical, biotech, and academic clients. Its core services include protein X-ray crystallography, BioNMR spectroscopy, crystallographic and WAC™ fragment screening, antibody epitope mapping, higher-order structure (HOS) analysis, and structure-based lead optimization, supported by its FastLane™ protein catalog and priority access to the MAX IV synchrotron beamlines.

Product overview

SARomics Biostructures offers an integrated structural biology and drug discovery services platform combining X-ray crystallography, BioNMR spectroscopy, proprietary WAC™ fragment screening technology, and FastLane™ off-the-shelf protein catalogs. The platform enables gene-to-structure workflows, crystallographic fragment screening, NMR-based higher-order structure analysis, and DNA-encoded library screening (in partnership with Vipergen). Key offerings include custom protein structure determination, antibody epitope mapping, biosimilar comparability studies, and structure-based lead optimization services for biotech, pharmaceutical, and academic clients worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

  • X-ray Crystallography Services

Quantifiable outcome

  • Over 100 structural biology and drug discovery projects completed annually
  • +4 more outcomes

Companies that use SARomics Biostructures

Customer profile

Named customers10 records

Segments3 records

Ideal customer profiles3 records

SARomics Biostructures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

SARomics Biostructures partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered major, core and minor.

  • Accelero Biostructures Inc.majorStrategic or Co-development Partner · 1 April 2026Strategic collaboration announced April 2026 combining structural biology services including protein X-ray crystallography and structure-based drug discovery. Aims to streamline workflows, reduce redundancy, and expand service capabilities. SARomics brings 20 years of experience, Accelero brings 10+ years.
  • Vipergen ApScoreStrategic or Co-development Partner · 11 November 2024Strategic partnership to offer enhanced hit and lead identification services combining Vipergen's DNA-encoded library (DEL) screening technologies with SARomics' structural biology capabilities. Vipergen's DEL screening can identify novel hits from over 500 million drug-like molecules, while SARomics provides detailed structural information including binding site mapping and binding poses.
  • LundaGUARD ConsortiumminorStrategic or Co-development Partner · 1 January 2020Consortium to fight infectious agents including LP3 (Protein Production Platform at Lund University), MAX IV, ESS, and University College London. Leverages WAC-screening platform for COVID-19 drug discovery.
  • Carna Biosciences Inc.majorChannel Partner/ Reseller/ Distributor · 1 August 2016Exclusive distribution agreement covering Japanese market for SARomics services.
  • Vectron BiosolutionsminorStrategic or Co-development Partner · 1 January 2010Partnership for customized gene-to-structure projects, utilizing Vectron's expertise in protein production and SARomics' expertise in protein crystallization and structure determination.
  • Red Glead DiscoverycoreStrategic or Co-development PartnerClose collaboration on integrated drug discovery projects including WAC fragment screening technology (jointly owned), gene-to-lead projects, and various pharmaceutical partnerships. Partners on EU projects including Virus-X, BIOCASCADES, and others.
  • MAX IV LaboratorycoreStrategic or Co-development PartnerPartnership for FragMAX fragment screening platform and access to BioMax and MicroMax beamlines for X-ray crystallography. Located just kilometers from SARomics labs at Medicon Village.
  • FragMAX Platform StaffcoreTechnology or IntegrationCollaboration on FragMAX platform for crystallographic fragment screening, including design of kinase-focused fragment library developed with Jens Carlsson, Szymon Pach, and Philip Ullmann from Uppsala University.

Scale indicators11 records

Recent moves8 records

Expansion highlights4 records

SARomics Biostructures competitors and assessment

Company assessment

Direct peers

  • Proteros Biotechnologies: Munich-based structural biology CRO offering protein crystallography, fragment screening (Pioneer™), and structure-based drug discovery services to pharma and biotech. Closest direct competitor to SARomics with very similar service portfolio and target customer base.
  • ZoBio: Dutch structural biology CRO specializing in protein crystallography, fragment screening by NMR and X-ray, and structure-based drug design. Highly comparable niche CRO competing for similar biotech and pharma accounts.
  • Domainex: UK-based CRO offering integrated drug discovery including protein crystallography, fragment screening, and medicinal chemistry. Comparable niche CRO targeting similar biotech and pharma customers.
  • Astex Pharmaceuticals: Fragment-based drug discovery specialist using X-ray crystallography and proprietary fragment libraries (e.g., Pyramid™). Direct overlap with SARomics' fragment screening and structure-based lead optimization services.

Broad incumbents

  • Evotec SE: Large global CRO/CDMO with structural biology and fragment-based drug discovery capabilities embedded in a much broader service portfolio. Represents the scaled incumbent SARomics competes against for larger pharma contracts.
  • Charles River Laboratories: Major CRO with extensive structural biology, protein sciences, and drug discovery offerings across a global footprint. Serves as the dominant scaled alternative for enterprises considering structural biology outsourcing.
  • Schrödinger, Inc. Computational chemistry and structure-based drug design platform with growing wet-lab/biopharma collaborations. Adjacent and partially overlapping in the structure-based design value chain.
  • WuXi AppTec: Massive global CRO/CDMO offering structural biology alongside a full suite of discovery, development, and manufacturing services. Represents a competitive threat on price, scale, and global account coverage.

Emerging players

  • Vipergen ApS: Danish DNA-encoded library screening technology provider. SARomics' partner in DEL screening services; comparable as an emerging platform player intersecting with SARomics' hit identification pipeline.

Regional players

  • Carna Biosciences: Japan-based kinase-focused drug discovery CRO and SARomics' exclusive Japanese distributor. Operates in adjacent kinase biology and serves as both a partner and a partial competitor in APAC structural biology services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

SARomics Biostructures social profiles

Digital presence

SARomics Biostructures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SARomics Biostructures leadership team

Management profile

Number of profiles

Profiles2 records

SARomics Biostructures funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SARomics Biostructures M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SARomics Biostructures

What does SARomics Biostructures do?

SARomics Biostructures is a contract research organization (CRO) that delivers fee-for-service structural biology and drug discovery projects for pharmaceutical, biotech, and academic clients. Its core services include protein X-ray crystallography, BioNMR spectroscopy, crystallographic and WAC™ fragment screening, antibody epitope mapping, higher-order structure (HOS) analysis, and structure-based lead optimization, supported by its FastLane™ protein catalog and priority access to the MAX IV synchrotron beamlines.

Is SARomics Biostructures a public or private company?

SARomics Biostructures is a private company. It is classified as venture growth investor backed and is currently operating.

When was SARomics Biostructures founded?

SARomics Biostructures was founded in 2006. It employs 11 to 50 people.

Where is SARomics Biostructures based?

SARomics Biostructures is headquartered in Lund, Sweden, in the Europe region.

How does SARomics Biostructures make money?

Two revenue lines are on record. Contract Research Services are the primary driver. The others are structural Biology Services.

Who are SARomics Biostructures's main competitors?

Direct peers on record are Proteros Biotechnologies, ZoBio, Domainex and Astex Pharmaceuticals. Broad incumbents are Evotec SE, Charles River Laboratories, Schrödinger, Inc. and WuXi AppTec. Vipergen ApS is listed as an emerging player. Carna Biosciences is listed as a regional player.

Does SARomics Biostructures have an API?

No public API is recorded for SARomics Biostructures.

What industry is SARomics Biostructures in?

SARomics Biostructures's product category is Structural Biology Contract Research Services. Its primary akta.pro industry code is HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity), with a secondary code of HLAGADAK, Material Characterization & Spectroscopy (NMR/FTIR/MS). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals